Table 4.

Randomized double-blind trials of DRPAs in other indications.

Indication	Aripiprazole	Brexpiprazole	Cariprazine
Alzheimer's dementia	Psychosis 3 RCTa vs. placebo: 1 study: NPI-NH p = 0.013 2 negative studies Agitation ARI im (10–15 mg) > PL	Agitation 2 RCTs vs. placebo: efficacy of 2 mg/d (CMAI) SMD = −3.77 (95% CI −7.38, −0.17), p = 0.040 SMD = −5.06 (95% CI −8.99, −1.13), p = 0.012	n/a
OCD (adjunctive therapy)	2 RCTs vs. placebo: YBOCS, WMD = 7.32 (95% CI −12.99, −1.66)	n/a	n/a
Tic disorder and Tourette syndrome	17 RCTs vs. active treatment vs. PL: SMD = −4.74 (95% CI −8.67, −1.06)	n/a	n/a
Autism spectrum disorder	3 RCTs vs. placebo: responses: RR = 2.08 (95% CI 1.24, 3.46); NNT = 4 (95% CI 2.8, 5.7)	n/a	n/a
Alcohol dependence	1 RCT vs. placebo: Days abstinent: 58.7 vs. 63.3% (n.s.) 1 RCT vs. naltrexone: Number of alcohol-free subjects: 12 vs. 11 (n.s.) number of relapsed subjects: 4 vs. 7 (n.s.)	n/a	n/a

n/a, no studies available; ARI im, aripiprazole intramuscular injection; CMAI, Cohen–Mansfield Agitation Inventory; NNT, number needed to treat; NPI-NH, Neuropsychiatric Inventory-Nursing Home; n.s., no significant difference; OCD, obsessive-compulsive disorder; PL, placebo; RCT, randomized controlled trial; RR, response rate; SMD, standardized mean difference; WMD, weighted mean difference; YBOCS, Yale–Brown Obsessive Compulsive Scale.